<DOC>
	<DOC>NCT02429440</DOC>
	<brief_summary>Clinical Phase I/II study to investigate the feasibility and tolerability of synthetic adjuvant peptide immunisation in combination with immune adjuvants (granulocyte macrophage colony stimulating factor; Montanide ISA-51) in patients with advanced renal cell cancer (RCC).</brief_summary>
	<brief_title>Adjuvant Antigen Specific Immunotherapy in Patients With Advanced Renal Cell Carcinoma Using Tumor Associated Peptides</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Freund's Adjuvant</mesh_term>
	<criteria>Advanced renal cell carcinoma clinical stage T3 or T4, N0, M0 N+, M0 M1 (after complete metastasectomy) ECOG performance status 0 or 1 age &gt;18 years at least 4 weeks since last administration of radiation or chemotherapy Serum levels of bilirubin &lt;2 mg/dl, creatinine&lt;2mg/dl detectable distant metastasis in radiological imaging (M1) patients unable to consent severe cardiopulmonary disorder (NYHA &gt;= 3) presence of secondary malignancy Immunosuppressive medication (last application of glucocorticoids &gt; 4 weeks) seizure pregnancy simultaneous participation in other active or passive immunisation treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>